{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-24-000024","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.674778+00:00","generated_at":"2026-05-31T11:52:13.932471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MoonLake reports $519.8M cash; initiates Phase 3 VELA in HS, positive FDA/EMA feedback for PsA Phase 3","bullets":["Q2 2024 cash, equivalents and short-term debt securities of $519.8M; cash runway to end-2026 unchanged.","R&D expenses $23.7M (up from $13.0M prior quarter) driven by new trial initiations; G&A $6.9M.","Phase 3 VELA program in hidradenitis suppurativa (HS) initiated; topline HiSCR75 primary endpoint expected mid-2025.","Positive FDA and EMA feedback on regulatory path for Phase 3 IZAR program in psoriatic arthritis; topline results expected end-2026.","Capital Markets Update on Sept 11; Phase 3 VELA TEEN in adolescent HS targeted for year-end 2024 initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-24-000024","json":"https://secwatch.observer/filing/0001821586-24-000024.json","markdown":"https://secwatch.observer/filing/0001821586-24-000024.md","text":"https://secwatch.observer/filing/0001821586-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000024/0001821586-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000024/mnlk-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:52:13.932471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}